A COVID-19 vaccine shows positive but somewhat disappointing results in the first stage of testing, according to a new study published Friday in The Lancet medical journal.
The vaccine tested in China triggered an immune response in most, but not all, patients, and many had negative side effects.
The study is the first to publish results from the initial phase of testing of a COVID-19 vaccine. More than 100 others are in development around the world, including nine others in clinical trials.
“If it was the only vaccine available, I think many people would take it,” said Gary Simon, head of the infectious disease division at George Washington School of Medicine and Health Sciences in Washington, D.C.
However, he added, “unless they can make it more tolerable, I can’t see how it’s going to be a major player.”
The small, preliminary trial tested 108 healthy volunteers in Wuhan, China, where the coronavirus first surfaced. The vaccine was developed by China-based CanSino Biologics with backing from the Chinese government.
After 28 days, half of those given low- or middle-dose levels of the vaccine produced neutralizing antibodies, the kind that would block infection. Three-quarters of those given the largest dose did.
Nearly all patients developed a positive response from a separate part of the immune system, within 14 days.
It’s not known yet whether either of these responses will be enough to protect patients. This early phase of testing is not designed to determine whether the vaccine works. It only tests whether the vaccine is safe and whether the immune system responds to it.
There were safety problems. The shot gave more than half the recipients sore arms. Nearly half developed a fever, including one serious case. About 40 percent had headaches or fatigue.
“Given that there was a safety issue, given that many patients didn’t have high [levels of] neutralizing antibodies, I would say this is a singularly unimpressive study,” said Paul Offit, director of the vaccine education center at Children’s Hospital of Philadelphia.
“I have no doubt there are going to be a number of vaccines that emerge that are going to be both safer and better than this vaccine appears to be,” Offit added.
The study covers only the first 28 days after injection. Final results will be evaluated in six months.
The vaccine is moving into a larger trial in Wuhan.
Leader of the pack
The report is the latest in a series of recent vaccine research announcements offering some tentative encouraging news.
Biotech company Moderna says its vaccine produced neutralizing antibodies in all eight patients for which it has results.
The company has not released the data, however, and scientists have expressed concerns about transparency.
But the studies also found signs that even if these vaccines keep people from getting sick, the shots might not stop them from spreading the disease.
Vaccinated animals still had the virus in their noses and throats. If the same thing happens in humans, and if those viruses can infect other people (both of which are far from certain at this point), then “to protect the population we’re going to have to be vaccinating many, many more people,” said Sarah Fortune, head of the infectious diseases department at Harvard T.H. Chan School of Public Health.
“I think it’s a little bit sobering to see that while we may get protection against disease,” she said, “we may not get nearly as effective protection against transmission.”
Offit said there is no way of knowing whether any of these vaccines is truly safe and effective until it’s been tested on tens of thousands of people.
“I think we should really wait and try not to predict what’s going to happen until we see the proof in the pudding,” he said.
With more than 335,000 dead and economies devastated worldwide, companies and governments are racing to produce a vaccine as soon as possible. Some are taking the unusual (and potentially costly) step of ramping up manufacturing of several vaccines before the proof is in.
Moderna has signed a deal to begin manufacturing its vaccine in July, with backing from the U.S. government.
The Trump administration announced that by October it would have at least 300 million doses of the Oxford vaccine available, through an agreement with pharmaceutical company AstraZeneca.
That timeline worries Offit.
“I can’t imagine that we would have the kinds of data we need to make sure that these vaccines are safe and effective,” he said.
“I just worry that there is a political drive to this, that they just want to make sure that we have something before the election” in November, he said.
“What we need are the data,” Offit added. “I hope this isn’t politicized.”
- DANGEROUS: Rich Areas In Los Angeles Have Lower Vaccination Rates Than The Poorest Places On Earth
- My little boy, 9, died just two days after catching the flu – more kids need to get vaccinated
- Study reveals just ONE dose of the HPV vaccine could be as effective as the standard 2-3 doses recommended by doctors
- How Hollywood stars ditch early critical success for high-paying flops: New survey shows Al Pacino and Robert De Niro have both swapped groundbreaking films for easy paydays but Angelina Jolie's career improves with age
- 54,917 million GB mobile data consumed till September: Trai
- There is a leftwing way to challenge big tech for our data. Here it is
- Glued to your office chair? Sitting for over nine hours a day can kill you early
- Make schools safe: Requiring vaccines in schools
- Parents Distrust, Delay Vaccines, Survey Finds
- Powered by Gates Foundation Cash, MIT Develop 'Tattoo ID' Tracking Who Has Had Vaccinations
- Liberty Vittert: Vaccinate your children — measles is back because fears and lies are trumping science
- Ragin' Cajuns' secret weapon? For last 19 years, Darren Walker has played major role in each win
- Kano Pillars boss Musa unimpressed after draw at Nasarawa United
- Majority of carmakers post decline in sales in Dec, Maruti Suzuki and M&M return to positive
- Vladimir Guerrero Jr. is finally coming to the majors -- here's how to evaluate his early performance
- Seven women in one family who had their breasts and ovaries removed after testing positive for 'Angelina Jolie gene' learn their results may have been WRONG - and there could be dozens more
- Improvement at this key position tops Ed Orgeron's wish list for LSU after big signing day haul
- Expected goals and Big Football Data: the statistics revolution that is here to stay
- De'Aaron Fox is Projected to Be the #19 Guard the Rest of the Season...Behind Devonte Graham and Ahead of Jaylen Brown
- Google Stadia has LAUNCHED under a cloud: Gamers with early access say streaming service is slow and has hidden costs as customers who pre-ordered the specialist kit were STILL waiting for it hours before it went live
Early COVID-19 Vaccine Data Positive, but 'Unimpressive' have 1144 words, post on www.voanews.com at May 22, 2020. This is cached page on Talk Vietnam. If you want remove this page, please contact us.